Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies

Haneen Shalabi,1,2 Vandana Sachdev,2 Amita Kulshreshtha,1 Julia W Cohen,1 Bonnie Yates,1 Doug R Rosing,2 Stanislav Sidenko,2 Cindy Delbrook,1 Crystal Mackall,1,3 Brandon Wiley,4,5 Daniel W Lee,1,6 Nirali N Shah1

ABSTRACT

Background Chimeric antigen receptor (CAR) T-cell-associated cytokine release syndrome (CRS) may present with tachycardia, hemodynamic instability and reduced cardiac function. Pediatric CAR studies examining cardiac toxicity are limited.

Methods We report on cardiac toxicity observed in children and young adults with hematologic malignancies enrolled in a CD19-28ζ CAR T-cell phase I trial (NCT01593696). All patients had a formal baseline echocardiogram. Real-time studies included echocardiograms on intensive care unit (ICU) transfer, and serial troponin and pro-B-type natriuretic peptide (pro-BNP) in the select patients.

Results From July 2012 to March 2016, 52 patients, with a median age of 13.4 years (range 4.2–30.3) were treated. CRS developed in 37/52 (71%), which was grade 3–4 CRS in nine patients (17%). The median prior anthracycline exposure was 205 mg/m² (range 70–620 mg/m²) in doxorubicin equivalents. The median baseline left ventricle ejection fraction (LVEF) and baseline LV global longitudinal strain (GLS) were 60% (range 50%–70%) and 16.8% (range 14.1%–23.5%, n=37) respectively. The majority, 76% (29/37), of patients had a reduced GLS <19% at baseline, and 6% (3/52) of patients had baseline LVEF <53%. ICU transfers occurred in 21 patients, with nine requiring vasoactive hemodynamic support and three necessitating >1 vasopressor. Six (12%) patients developed cardiac dysfunction (defined by >10% absolute decrease in LVEF or new-onset grade 2 or higher LV dysfunction, per CTCAE v4), among whom 4 had grade 3–4 CRS. Troponin elevations were seen in 4 of 13 patients, all of whom had low LVEF. Pro-BNP was elevated from baseline in 6/7 patients at the onset of CRS, with higher levels correlating with more severe CRS. Cardiac dysfunction fully resolved in all but two patients by day 28 post-CAR.

Conclusion Cardiac toxicity related to CD19-28ζ CAR T-cell-associated CRS was generally reversible by day 28 postinfusion. Implementation of more frequent monitoring with formal echocardiograms incorporating systemic analysis of changes in GLS, and cardiac biomarkers (troponin and proBNP) may help to earlier identify those patients at highest risk of severe cardiac systolic dysfunction, facilitating earlier interventions for CRS to potentially mitigate acute cardiac toxicity.

INTRODUCTION

Chimeric antigen receptor (CAR)-modified T-cells targeting CD19 have proven benefit for the treatment of multiply relapsed or refractory CD19+ acute lymphoblastic leukemia (ALL).1–9 Tisagenlecleucel, a CD19/4-IBB CAR T-cell product, received US Food and Drug Administration approval in 2017 for pediatric and young adult patients with B-cell ALL that is refractory or in second or greater relapse. The application of CAR T-cells for the treatment of ALL continues to broaden.10

Cytokine release syndrome (CRS), a systemic inflammatory response syndrome due to supraphysiological immune system activation, is recognized as a potentially life-threatening adverse effect of CAR T-cell therapy.1 3 10–15 While mild CRS can be self-limited, manifesting with flu-like symptoms and fever, severe CRS can be marked by hypotension, hypoxia and end-organ dysfunction.10 16 Cardiovascular dysfunction is a significant and yet incompletely defined aspect of CRS. The hemodynamic abnormalities associated with CRS can range from tachycardia to life-threatening hypotension.

The dynamics of CRS-associated cardiac dysfunction are not well established17 18 and there is a paucity of available information, particularly, in children.19 One anti-CD19 CAR T-cell trial documented shock requiring vasoactive infusion in 13.6% of participants.20 Experiences to date suggest that clinically significant hypotension due to CRS (grades 3–4) occurs in 92%–38% of patients receiving CAR T-cell therapy.3 6 9 Based on a single-institution review of pediatric patients, predictors of hypotension requiring inotropic support include patients with pretreatment leukemic blast count >25% or pre-existing cardiac dysfunction.21 Considering the
patient population receiving CAR T-cell therapy may have pre-existing cardiac dysfunction due to prior anthracycline therapy and/or radiation exposure, we recognize that this population may be particularly vulnerable to cardiac complications. It is important to gain a more comprehensive understanding of the cardiovascular side effect profile of CRS in an effort to understand risk factors and optimize management strategies for its associated cardiotoxicity.22

In this report, we systematically reviewed the experience of cardiotoxicity seen with CD19-28ζ CAR T-cell therapy for pediatric and young adult patients receiving this investigational therapy at the National Cancer Institute. Limited real-time cardiac monitoring was combined with a retrospective analysis of baseline cardiac profiles and risk factors within this patient population. Specifically, we evaluated the association between severity of CRS and the development of cardiac dysfunction. We additionally explored the feasibility and utility of serial cardiac biomarker testing (troponin and pro-B-type natriuretic peptide (proBNP)) as an indicator of myocardial injury and cardiac dysfunction in the setting of CD19 CAR T-cell therapy.

METHODS
In this retrospective analysis, we systematically evaluated cardiac toxicity in patients treated with autologous T-cells engineered to express a CD19 CAR incorporating an anti-CD19 single-chain variable fragment plus T-cell receptor ζ and CD28 signaling domains in a phase I clinical trial approved by the National Cancer Institute Institutional Review Board (NCT01593696). Eligible patients were aged 1–30 years with CD19+ B ALL or non-Hodgkin lymphoma, relapsed or refractory to standard therapy plus at least one salvage regimen and were treated between July 2012 and May 2016. Per protocol, all patients had to be >14 days from systemic chemotherapy (including anthracyclines) and must have recovered from the acute side effects of their prior therapy.

The following pretreatment characteristics were abstracted from medical records: oncologic diagnosis, Lansky/Karnofsky performance status, bone marrow blast percentage, central nervous system disease status, extramedullary disease status, previous treatment (chemotherapy, immunotherapy, radiation therapy and hematopoietic stem cell transplant (HSCT)), cumulative anthracycline dose, and any prior receipt of dexrazoxane (if available). In addition, the lymphodepleting chemotherapy regimen, CAR T-cell dose, CRS grade and any required treatment for management of CRS (tocilizumab, corticosteroids) were recorded. CRS was graded using Lee criteria,13 and ASTCT consensus CRS grading was retrospectively incorporated.23 Other details about the clinical course during CRS, including hypotension-requiring vasoactive support and requirement for mechanical ventilation, were also obtained.

All patients had formal baseline transthoracic echocardiograms performed using commercially available systems with measurements performed according to American Society of Echocardiography guidelines.24 The left ventricular ejection fraction (LVEF) was calculated using the biplane Simpson’s formula (normal ≥53%). During the trial, real-time monitoring including cardiology consultation, echocardiograms, and serial cardiac evaluations (specifically troponin and pro-BNP assays) based on clinical status were performed in a limited subset of patients after the non-fatal cardiac arrest of patient 14.6 Best practice guidelines were used depending on the clinical scenario.

Global longitudinal strain (GLS), a measure of myocardial deformation used to detect subclinical LV dysfunction, was measured retrospectively on previously performed echocardiograms using specialized strain software (EchoInsight, Epsilon Imaging, Ann Arbor, Michigan, USA). Strain values were compared with reference ranges provided in a recent meta-analysis.25 The GLS data are expressed as absolute value (%). Formal follow-up echocardiogram reports, troponin and pro-BNP levels were available in a subset of patients. Tachycardia was defined by >100 beats per minute in patients≥18 years old and adjusted for baseline pediatric normal values in those <18 years old.26

The primary endpoint was cardiac dysfunction defined as ≥10% absolute decrease in LVEF compared with baseline or new-onset LV systolic dysfunction (grade 2, LVEF <50%). Severe cardiac dysfunction was defined by new onset LV systolic dysfunction ≥grade 3 or LVEF <40%, using CTCAE V.4.0.27 On trial,≥grade 3 hypotension (sustained ≥24 hours of therapy or hypotension requiring vasopressor support) was captured. Elevated troponin levels above normal values and elevation in pro-BNP above patients’ baseline were secondary endpoints. All patients who were treated were included in the data extraction and analysis, with impact of CRS on cardiac toxicity limited to those who had CRS.

Statistical methods
Enrollment characteristics were analyzed as descriptive variables, with summary statistics calculated. Baseline characteristics were summarized as number and percentage of patients for categorical variables and median and range for continuous variables. We compared the distribution of the paired outcome variable LVEF and proBNP between pre-CAR and post-CAR using Wilcoxon rank sum test. Post-CAR nadir LVEF and peak proBNP values were used for assessment. Fisher’s exact tests was used to compare outcomes between two categorical variables comparing those with and without cardiac dysfunction. Mann-Whitney U tests were used to compare unpaired data sets. Statistical analyses were performed using Prism software, with a two-tailed p<0.05 used to assess for statistical significance.
RESULTS

All patient characteristics (n=52)

Baseline characteristics for the 52 patients treated with CD19 CAR T-cells are shown in Table 1. The median age was 13.4 years (range 4–30). Fifty patients had ALL, 2 had non-Hodgkin’s lymphoma. Thirty-nine patients (75%) had multiply relapsed disease, while 13 patients (25%) had primary refractory disease. Twenty-three patients (44%) had undergone at least one prior allogeneic total body irradiation (TBI)-based HSCT, and 11 patients (21%) had undergone prior immunotherapy. The median Lansky/Karnofsky performance status was 90% (range 40%–100%). All patients had prior anthracycline exposure, with a median of 205 mg/m² (range 70–620). The median baseline LVEF was 60% (range 50–70), and 3 patients had abnormal LVEF <53% at the time of study enrollment. GLS data was retrospectively analyzed on previously performed echocardiograms in 37 patients. Fifteen patients did not have images of adequate quality and frame rate to calculate baseline GLS data (2 studies were performed at an outside hospital, 13 studies from our hospital were technically difficult). Median baseline LV GLS was 16.8% (range: 14.1%–23.5%, n=37), with 78% (29/37) of patients having a reduced GLS (<19%) at baseline.28

CRS characteristics (n=37)

Restricted to the 37 patients who developed CRS, characteristics and outcomes are described below and are shown in Table 2. The median time to onset of CRS was 5 days (range 1–12), with 28 of 37 patients (76%) developing grades 1–2 CRS, and 9 patients (24%) developing grades 3–4 CRS. Seven patients with grade 3 or 4 CRS received tocilizumab, 4 of whom also received concurrent steroids. Thirty-three patients with CRS had at least one formal echocardiogram performed post-infusion, 19 of whom had echocardiograms done during CRS at a median time of 6 days (range 2–12) postinfusion.

Table 1  Patient demographics

|                      | All treated subjects n=52 | Cardiac dysfunction n=6 | No cardiac dysfunction n=46 | P value* |
|----------------------|---------------------------|-------------------------|----------------------------|---------|
| Age, median (range), year | 13 (4–30)                | 18 (10–30)              | 13 (4–27)                  | 0.059   |
| Male, n (%)          | 41 (78.8)                 | 6 (100)                 | 35 (76.1)                  | 0.32    |
| Diagnosis            | ALL, n (%)                | 50 (96.1)               | 5 (83.3)                   | 0.22    |
|                      | NHL, n (%)                | 2 (3.8)                 | 1 (16.7)                   |         |
| Primary refractory   | 13 (25)                   | 3 (50)                  | 10 (21.7)                  | 0.34    |
| Prior lines of therapy >4, n (%) | 9 (17.3)          | 0 (0)                   | 9 (19.6)                   |         |
|                      | 2–4, n (%)                | 43 (82.7)               | 6 (100)                    |         |
| Prior HSCT           | 0, n (%)                  | 29 (55.8)               | 3 (50)                     | 26 (56.5) | 1.00   |
|                      | 1, n (%)                  | 18 (34.6)               | 3 (50)                     | 15 (32.6) |
|                      | 2, n (%)                  | 5 (9.6)                 | 0 (0)                      | 5 (10.9)  |
| Prior TBI, n (%)     | 23 (44)                   | 3 (50)                  | 20 (43.4)                  | 1.00    |
| Prior immunotherapy, n (%) | 11 (21.1)           | 1 (16.7)                | 10 (21.7)                  | 1.00    |
| Prior anthracycline exposure, median (range), doxorubicin equivalents | 205 (70–620) | 275 (110–571) | 205 (70–620) | 0.23    |
| Baseline left ventricular ejection fraction, median (range), % | 60 (50–70) | 61 (50–70) | 60 (50–72) | 0.59    |
| Baseline left ventricular global strain, median (range), % n=37 | 16.8 (11.6 to 23.5) | 14.4 (11.6 to 18.7)† | 17 (14.1 to 23.5) | 0.04    |
| Performance status, median (range) % | 90 (40–100) | 80 (40–90) | 90 (50–100) | 0.07    |

Cardiac dysfunction is defined as a >10% absolute decrease in left ventricular ejection fraction (LVEF) compared with baseline or new onset left ventricular systolic dysfunction ≥grade 2, LVEF <50%. Any biological therapy used to treat cancer, for example, CAR T cells, antibody-based therapy.

*The p value is comparing baseline characteristics of those with and without cardiac dysfunction. Global longitudinal strain (GLS) is presented in absolute numbers (%).

†Only four patients had baseline GLS measured.

ALL, acute lymphoblastic leukemia; CAR, chimeric antigen receptor; HSCT, Hematopoietic stem cell transplant; NHL, non-Hodgkin’s Lymphoma; TBI, total body irradiation.
Twenty-one patients (57%) who had CRS required transfer to the intensive care unit (ICU), nine patients (24%) developed hypotension-requiring vasopressor support, with three patients requiring two or more vasopressor agents for hypotension. All patients who required vasopressor agents received norepinephrine as a first line agent, with the addition of vasopressin (n=3) and epinephrine (n=1) as second- and third-line agents, respectively. The median peak dose of norepinephrine received in these patients was 8 μg/kg/min, (range 0.15–45 μg/kg/min). One patient, previously described6 and further outlined below, developed reversible cardiac arrest, and was the only patient who required milrinone for cardiac support. The median time to initiation of vasopressor support was 6 days post-CAR T-cell infusion (range 3–8 days), and the median duration of vasopressor support was 3 days, (range 1–7 days). Three of nine patients requiring vasopressor support developed new cardiac dysfunction during their CRS course, with findings of LV systolic dysfunction (table 3).

No clinically apparent cardiac dysfunction occurred in the 15 patients who did not develop CRS; 13/15 patients had postinfusion formal echocardiograms performed at a median of 25 days (range 7–47) postinfusion. All echocardiograms demonstrated stable cardiac function as compared with the preinfusion echocardiogram.

Cardiac dysfunction post-CAR T-cell therapy (n=6)
Six of 37 patients with CRS (16%) developed cardiac dysfunction, all of which occurred during the clinical course of CRS (table 3 and figure 1A) and all of whom required transfer to the ICU. Among nine patients with >grade 3 CRS, 4 (44%) developed cardiac dysfunction. There was a greater likelihood of patients with cardiac dysfunction developing CRS earlier (median 2.5 days post CAR T-cell infusion, p=0.015), having severe CRS (≥grade 3, p=0.022) and receiving tocilizumab (p=0.006), but there was no association between development of cardiac dysfunction and administration of steroids (p=0.11). Those that developed cardiac dysfunction on
trial had a significantly lower baseline GLS ($p = 0.040$) as compared with those that did not develop cardiac dysfunction, however, there was no significant difference seen in baseline LVEF ($p = 0.59$) between the two groups (Table 1). No patients on study developed a clinically relevant arrhythmia. However, on day 4 of CRS, Patient 14 developed cardiac arrest but recovered following aggressive management, including temporary mechanical circulatory support (intra-aortic balloon pump). This patient received tocilizumab and steroids for grade 4 CRS. This patient’s cumulative lifetime anthracycline dose was 360 mg/m², and he had a baseline LVEF of 64%, with substantial decrease in LVEF, to a nadir of 20% on day 5 of CRS. Peak troponin level (6.23 ng/mL) was observed on day 4 of CRS.

Resolution of cardiac dysfunction was observed in four of the six patients by day 28 post-CAR T-cell infusion, including patient 14. Two patients had persistent cardiac dysfunction with decreased LVEF at day 28. One of these patients had the lowest LVEF (10%) during CRS.

### Table 3 Characteristics of patients with cardiac dysfunction

| Patient | Prior anthracycline exposure (mg/m²) | Baseline LVEF, % | Lowest LVEF, % | Max CRS* grade | Vasoactive support? | Troponin elevation? | Peak troponin (ng/mL) |
|---------|-------------------------------------|------------------|----------------|---------------|---------------------|---------------------|----------------------|
| 14      | 360                                 | 64               | 20             | 4             | Yes                 | Yes                 | 6.23                 |
| 16      | 110                                 | 70               | 45             | 4             | No                  | Yes                 | 0.117                |
| 39      | 195                                 | 60               | 25             | 3             | No                  | Yes                 | 0.113                |
| 45      | 570                                 | 55               | 10             | 4             | Yes                 | No†                 | <0.010               |
| 51      | 355                                 | 50               | 40             | 2             | No                  | No†                 | <0.010               |
| 52      | 180                                 | 61               | 45             | 2             | Yes                 | Yes                 | 0.016                |

Cardiac dysfunction is defined as a >10% absolute decrease in left ventricular ejection fraction (LVEF) compared with baseline or new onset left ventricular systolic dysfunction >grade 2, LVEF <50%.

*CRS max grade as per Lee et al, Blood 2014.
†Troponin levels were drawn and undetectable, lower limit of detection 0.010 ng/mL.

CRS, cytokine release syndrome.

Figure 1  
(A) Left ventricular EF (%) in all patients with CRS. Each line represents a patient’s EF during the course of CRS as determined by echocardiogram. Black lines indicate those patients with CRS who had preserved EF; without cardiac dysfunction. Red lines indicate those patients with CRS who had decreased EF and experienced cardiac dysfunction. (B) Cumulative anthracycline dose for all patients treated on CD19-28ζ CAR T-cell trial stratified by those who had decreased EF (min: 100 mg/m², max: 570 mg/m²) and those that had preserved EF (min: 70 mg/m², max: 620 mg/m²) as compared with their baseline echocardiograms. (C) Pre-CAR and Post-CAR T-cell therapy proBNP levels in seven patients. Two patients with the highest post-therapy pro-BNP levels (depicted by the *) had decreased EF and cardiac dysfunction. CAR, chimeric antigen receptor; CRS, cytokine release syndrome; pro-BNP, pro-B-type natriuretic peptide.
and the other had a modest decrease in LVEF from baseline (50%–40%); however, both patients recovered to baseline by the 3 months time point. Additionally, these two patients had among the highest baseline anthracycline exposure, 570 mg/m² and 355 mg/m² respectively (figure 1B).

In 16 of 37 patients, echocardiograms performed during CRS had appropriate image views available to retrospectively analyze LV GLS. These echocardiograms were performed at a median of 5.5 days post-CAR infusion (range 2–12), and all 16 patients had abnormal LV GLS, with a median of 14.1% (range: 5.3%–17.9%). 14/16 patients with CRS had pre-GLS and post-GLS measurements (two patients did not have baseline LV GLS available for comparison) and 64.2% (9/14) had relative reduction in GLS >15%. This included three patients with normal strain at baseline, who developed abnormalities post CAR T-cell infusion. All six patients that developed cardiac dysfunction (defined by decreased EF) during CRS had concurrent abnormal myocardial strain, with a median LV GLS of 10.1% (range 5.3%–14.1%). Tables incorporating outcomes stratified by those patients with a significant relative decline in GLS >15% (6 additional patients) has been added as online supplementary file.

Thirteen patients had real-time conventional troponin assays measured during their CRS course as clinically indicated. Of the patients that were tested, 30.7% (4/13) had abnormal troponin, and all four of these patients had cardiac dysfunction measured by decreased LVEF. There was a limited cohort of patients (n=7) with proBNP monitoring, at baseline and serially after CAR T-cell infusion, with peak pro-BNP recorded as post-CAR time point. In this cohort, pro-BNP levels were elevated during CRS, with the highest elevations observed in two patients with cardiac dysfunction that developed during CRS (figure 1C).

**DISCUSSION**

As the indications for CAR T-cell therapy broaden, understanding the full spectrum of the toxicity profile is critical in order to safely treat patients. CRS, the main toxicity of CAR T-cell therapy, is associated with a host of cardiac manifestations which may include tachycardia, decrease in EF and hypotension, among others.15 21 We report on the first pediatric study evaluating cardiotoxicity and its relationship to CRS in children and young adults who received a CD19-28ζ CAR construct.5 6 8

Notably, patients referred to this study were heavily pretreated, having received a median of 4 chemotherapy cycles, with all patients exposed to anthracycline-containing regimens, and 44% of patients having had a prior HSCT and TBI. It is hypothesized that patients who have a significant history of anthracycline exposure or TBI may have inadequate cardiac reserve to sustain cardiovascular insults like those associated with CRS. LV strain measurements are emerging as a powerful tool in screening and monitoring patients undergoing potentially cardiotoxic therapies. Baseline and longitudinal abnormalities in GLS are used to detect subclinical LV dysfunction and may have additive value over EF and other imaging and clinical parameters.29 Among our baseline echocardiograms, only 6% (3/52) had abnormal EFs. In contrast, a substantial fraction of patients, 78% (29/37), had baseline abnormal GLS, reflective of possible cardiac toxicity from previous anthracycline exposure or irradiation history. While the subgroup of six patients developing cardiac dysfunction was too small to demonstrate predictive value of GLS, closer imaging surveillance in high-risk patients may allow earlier detection of cardiac abnormalities. Indeed, when retrospective analysis of pre-GLS and post-GLS values were performed, an additional six patients were identified as having subclinical LV cardiac dysfunction (online supplementary tables). Thus, prospective and real-time GLS monitoring preinfusion and postinfusion may provide valuable information and potentially earlier identification of acute and subacute cardiac strain that may impact a patients’ toxicity profile and the treatment thereof.

Although a majority of patients developed some cardiac toxicity on this study, the most common manifestation was sinus tachycardia observed in 36 of 37 patients with CRS. More significant cardiac dysfunction defined by decreased EF occurred in 6 of 37 (16%) patients who developed CRS (and in 6 of 52 (12%) of all treated patients). No patients on this study developed cardiac dysfunction independent of CRS. This is in line with the experience described by Burstein et al,41 who retrospectively demonstrated new systolic dysfunction in 10% of CAR T-cell treated children. In our high-risk patient population with refractory disease, our data suggest that cardiovascular toxicity associated with CAR T-cell therapy in children and young adults is both limited and reversible. Recognizing that more follow-up is needed, long-term dysfunction was not seen in our study or other recent reports.17 19 21

While shock associated with CRS is primarily vasodilatory in nature, due to capillary leak, patients may only be transiently responsive to fluid resuscitation, thus necessitating vasoactive medications. Furthermore, a mixed vasodilatory and cardiogenic shock picture may be seen, thus necessitating additional inotropic support. In this study, 17% of all patients treated with CAR T-cells developed hypotension-requiring pressor medication, with only one patient requiring inodilator support with milrinone.

Utilization of biomarkers was obtained in this study in real time in a limited cohort of patients. Provider practice differences led to varying cases and times in which biomarkers were obtained. Serial proBNP levels measured pre-CAR and post-CAR T-cell infusion demonstrated proBNP elevation during CRS, with two of six patients who had decreased LVEF having peak elevations in proBNP during CRS. Additionally, myocardial injury indicated by troponin elevation was noted in 4 of 13 patients, all of whom had significant cardiac dysfunction defined by depressed LVEF. Although the number of patients tested was small, performing serial evaluations of these...
in our cohort, severe CRS was associated with a higher likelihood of developing cardiac dysfunction. Recent data supports the utilization of early intervention with tocilizumab and/or steroids to reduce the severity of CRS in an effort to improve outcomes and toxicity profiles, without impacting antileukemia activity. Furthermore, the aforementioned study in adults receiving CAR T-cell therapy found that a delay in administration of tocilizumab for CRS was associated with a 1.7-fold increase in cardiovascular events. Thus we anticipate as pre-emptive CRS mitigation strategies are more readily employed, impact of CRS on cardiac dysfunction may be lessened.

Limitations to this study include the largely retrospective nature, especially with regard to analysis of the first 13 patients as comprehensive cardiac monitoring (eg, formal echocardiograms) of patients who went to the ICU was not incorporated until after patient 14. Thus, some patients earlier in the study may have developed transient cardiac dysfunction, which was not recognized. While it is highly unlikely that severe cardiac dysfunction would go unnoticed, the number of patients with any cardiac toxicity may be underrepresented. Additionally, cardiac workup was subject to provider discretion. Although some real-time evaluations were performed during the course of the study, frequency of studies and medications given were at the discretion of the treating physician. Another limitation to our study is that pretherapy and post-therapy pro-BNPs were not routinely performed on all patients. Treating physicians were more likely to obtain serial proBNPs on those who had cardiac dysfunction defined by echocardiogram, thus limiting our ability to perform multivariate analysis and make definitive conclusions regarding these results and the applicability to the broader CAR T-cell population. Also, the use of conventional troponin assays, as compared with high-sensitivity troponin assays, measuring biomarkers may have missed patients with subtle cardiac stress. However, the sensitivity of the conventional troponin assay is adequate to detect myocardial injury in those with clinically meaningful depressed LVEF such as patient 45, who had serial troponin levels measured during the course of CRS, all of which were undetectable. Finally, this was a single institution study, with a small number of patients, thereby limiting the power of our findings. Future steps include establishing a CAR T-cell consortium with multiple institutions who treat pediatric and young adult patients in order to systematically collect and analyze toxicity data and centralize such results in an effort to better identify patterns of late toxicities.

There is currently no systematic guidance on how to monitor for post CAR T-cell cardiac toxicity, or provisions for how long the duration of monitoring should continue in children. The findings in this study support the need for a systematic approach for the management of CRS-associated cardiotoxicity that incorporates close clinical surveillance. We provide an algorithm (figure 2) to systematically and prospectively monitor pediatric patients receiving CAR T-cells for cardiac toxicity, with

![Image 40x360 to 288x745](http://jitc.bmj.com/)

**Figure 2** Cardiac screening and monitoring algorithm for pediatric and young adult patients undergoing CAR T-Cell Therapy. *Obtain cardiology consult in patients with a history of heart failure (preserved or reduced ejection fraction (EF), known cardiomyopathy, cardiac arrhythmias, prior chest/mediastinum radiotherapy, baseline BNP or troponin elevated above upper limit of normal. Consider cardiology consult in patients with asymptomatic LV dysfunction (LVEF <53% or abnormal GLS) or cumulative anthracycline dose >300 mg/m²; Monitor for conduction abnormalities and QT prolongation; High-risk patients include those that required cardiology consult prior to infusion; Consider cardiac MR in patients with new or worsened LV dysfunction (LVEF <53% or drop in GLS <15% from baseline) that has persisted after CAR T-cell therapy. BNP, B-type natriuretic peptide; CAR, chimeric antigen receptor; CRS, cytokine release syndrome; GLS, global longitudinal strain; TTE, transthoracic echocardiogram.

biomarkers was feasible and may be helpful in identifying high risk patients who may benefit from earlier medical intervention during CRS. Indeed, a recently published study in adult oncology patients demonstrated that cardiac injury and cardiovascular events were common post-CAR T-cell therapy, with 95% of their events occurring after an elevated troponin.
monitoring of high-risk patients until resolution of the aforementioned toxicities to baseline. This guidance incorporates cardiac enzymes, EKGs and echocardiograms at various time points during the course of CAR therapy with the hope of broad implementation that will facilitate cross-trial comparisons of cardiac toxicity. These studies should allow for rapid recognition of cardiac side effects in patients with CRS and allow for timely and optimal therapy. To this end, early consultation with cardiologists and ICU providers to help with management of patients, especially with hemodynamic support, is imperative.

In conclusion, this study of patients treated with CD19-28ζ CAR T-cells demonstrates that cardiotoxicity associated with CRS is limited and generally reversible with severe cardiac dysfunction occurring less frequently. A systematic approach of clinical surveillance and comprehensive cardiac evaluations would facilitate earlier identification of patients at high risk of developing severe cardiac dysfunction.

Acknowledgements We gratefully acknowledge the study participants and their families, referring medical care teams, the faculty and staff of the NIH Clinical Center who provide their expertise in the management of the study participants, and the data managers, Showri Kakumanu and Ekaterina Nikitina, involved with this work. This work was supported in part by the Intramural Research Program, National Cancer Institute and NIH Clinical Center, National Institutes of Health.

Contributors HS, VS and NWS wrote the first version of the manuscript. DWL, NNS, BY and CM designed the study and did primary data analysis. DWL, NNS, BY, HS, CM, VS, JWC, DRR and BW provided critical input and contributed to writing of the manuscript. DWL, NNS, BY, CM, BW and SS designed the study and did primary data analysis. DWL, NNS, BY, CM, BW and SS designed the study and did primary data analysis. DWL, NNS, BY, CM, BW and SS designed the study and did primary data analysis.

Patient consent for publication Not required.

Ethics approval This clinical trial was approved by the National Cancer Institute Institutional Review Board (IRB). The trial was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. All data relevant to the study are included in the article or uploaded as online supplementary information. Data are available on request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

ORCID iD Haneen Shalabi http://orcid.org/0000-0001-8692-8034

REFERENCES

1. Hay KA. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR) T cell therapy. Br J Haematol 2018;183:364–74.

2. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509–18.

3. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507–17.

4. Maude SL, Teachey DT, Porter DL, et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 2015;125:4017–23.

5. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018;378:439–48.

6. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015;385:517–28.

7. Park JH, Riviere I, Long-Term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 2018;378:449–59.

8. Gardner RA, Finney O, Annesley C, et al. Intent-To-Treat leukemia remission by CD19 T CAR cells of defined formulation and dose in children and young adults. Blood 2017;129:3320–21.

9. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28ζ CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra225.

10. Frey NV. Chimeric antigen receptor T cells for acute lymphoblastic leukemia. Am J Hematol 2019;94:S24–7.

11. Maude SL, Barnett D, Teachey DT, et al. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 2014;20:119–22.

12. Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 2016;6:664–79.

13. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124:188–95.

14. Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015;33:540–9.

15. Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 2017;130:2295–306.

16. Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev 2019;34:45–55.

17. Avi RM, Frigault MJ, Bradly MG, et al. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol 2019;74:13099–108.

18. Granata S, Carver JR, Hayek SS, et al. Chimeric antigen receptor T-cell therapy for cancer and heart: JACC Council perspectives. J Am Coll Cardiol 2019;74:3153–63.

19. Asnani A. Cardiotoxicity of immunotherapy: incidence, diagnosis, and management. Curr Oncol Rep 2018;20:44.

20. Kochenderfer JN, Somerville RPT, et al. Recommendations for cardiac follow-up of CD19 chimeric antigen receptor T cell therapy associated with high serum interleukin-15 levels. JAMA Cardiol 2018;3:e182045.

21. Burstein DS, Maude S, Grupp S, et al. Cardiac profile of chimeric antigen receptor T cell therapy in children: a single-institution experience. Biol Blood Marrow Transplant 2018;24:1590–5.

22. Guha A, Armanious M, Bradly MG. Update on cardiac-oncology: novel cancer therapeutics and associated cardiotoxicities. Trends Cardiovasc Med 2019;29:20–9.

23. Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019;25:625–38.

24. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr 2015;28:e14–1–39.

25. Levy PT, Machefsky A, Sanchez AA, et al. Reference ranges of left ventricular strain measures by two-dimensional Speckle-Tracking.
echocardiography in children: a systematic review and meta-analysis. *J Am Soc Echocardiogr* 2016;29:e206:209–25.
26 Kleinman K. *Harriet Lane handbook: a manual for pediatric house officers*. 22nd edition. Philadelphia: ELSEVIER, 2021.
27 Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of echocardiography and the European association of cardiovascular imaging. *J Am Soc Echocardiogr* 2014;27:311–39.

28 Sawaya H, Sebag IA, Plana JC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. *Circ Cardiovasc Imaging* 2012;5:596–603.
29 Clasen SC, Scherrer-Crosbie M. Applications of left ventricular strain measurements to patients undergoing chemotherapy. *Curr Opin Cardiol* 2018;33:493–7.
30 Gardner RA, Ceppi F, Rivers J, et al. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. *Blood* 2019;134:2149–58.